Comparing the dynamics of biomarkers of neuron-specific enolase and S-100 protein in neonates with hypoxic-ischemic encephalopathy, depending on the start of therapeutic hypothermia (0–6 h vs. 6–24 h after delivery)
Background. To date, it remains unclear whether serum levels of neuron-specific enolase (NSE) and S-100 protein definitely correspond to the severity and possible outcomes of hypoxic-ischemic encephalopathy (HIE), as well as their dynamics during the acute period of HIE, depending on the time when therapeutic hypothermia was started. The purpose was to evaluate the dynamics of such serum biomarkers as NSE and S-100 protein in full-term newborns during the acute period of HIE, depending on the time when therapeutic hypothermia was initiated. Materials and methods. A prospective, single-center cohort study was performed in 205 full-term infants treated in the neonatal intensive care unit (NICU) due to hypoxic-ischemic encephalopathy in 2012–2017. All the babies were stratified by the period from delivery to admission in the NICU. Serum concentrations of NSE and S-100 protein were determined on days 1, 3 and 5 of treatment both in the general cohort and in groups: 0–6 hours (group 1, n = 56) and over 6 hours of life (group 2, n = 149). Results. Dynamics of S-100 significantly changed during 5 days in both groups of newborns (p < 0.001). However, no significant difference was found in the trends of S-100 protein concentration during the first 5 days in both groups (p = 0.082). There was also no statistically significant difference between serum concentrations of S-100 (p = 0.320) in patients admitted in 0–6 hours and later for all five days, except for the first day of admission (p = 0.002). There was no statistically significant difference in NSE level within groups, both in the dynamics from day 1 to day 5 (p = 0.217) and compared to the early (0–6 h) or late (> 6 h) admission to the NICU (p = 0.845). There is also no significant difference in the concentration of NSE among the groups (p = 0.719). Conclusions. No significant differences in the dynamics of S-100 protein and NSE levels in newborns 0–6 hours and over 6 hours after delivery indicated the possibility of initiating therapeutic hypothermia 6 hours after birth, if it wasn’t started earlier because of organizing reasons
Full Text:PDF (Українська)
Arnaez J, García-Alix A, Arca G, et al; Grupo de Trabajo EHI-ESP. Incidence of hypoxic-ischaemic encephalopathy and use of therapeutic hypothermia in Spain. An Pediatr (Barc). 2018;89(1):12-23. doi: 10.1016/j.anpedi.2017.06.008.
Lee AC, Kozuki N, Blencowe H, et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatr Res. 2013 Dec;74 Suppl 1:50-72. doi: 10.1038/pr.2013.206.
Chalak LF, Sánchez PJ, Adams-Huet B, Laptook AR, Heyne RJ. Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy. J Pediatr. 2014 Mar;164(3):468-74.e1. doi: 10.1016/j.jpeds.2013.10.067.
Qian J, Zhou D, Wang YW. Umbilical artery blood S100 beta protein: a tool for the early identification of neonatal hypoxic-ischemic encephalopathy. Eur J Pediatr. 2009 Jan;168(1):71-7. doi: 10.1007/s00431-008-0711-4.
Muniraman H, Gardner D, Skinner J, et al. Biomarkers of hepatic injury and function in neonatal hypoxic ischemic encephalopathy and with therapeutic hypothermia. Eur J Pediatr. 2017;176(10):1295-1303. doi: 10.1007/s00431-017-2956-2.
Massaro AN, Chang T, Baumgart S, McCarter R, Nelson KB, Glass P. Biomarkers S100b and NSE predict outcome in hypothermia-treated encephalopathic newborns. Pediatr Crit Care Med. 2014 Sep;15(7):615-22. doi: 10.1097/PCC.0000000000000155.
Chaparro-Huerta V, Flores-Soto ME, Merin Sigala ME, Barrera de León JC, de Lourdes Lemus-Varela M, de GuadalupeTorres-Mendoza BM. Proinflammatory cytokines, enolase and S-100 as early biochemical indicators of hypoxic-ischemic encephalopathy following perinatal asphyxia in newborns. Pediatr Neonatol. 2017 Feb;58(1):70-76. doi: 10.1016/j.pedneo.2016.05.001.
Simon-Pimmel J, Lorton F, Masson D, Bouvier D, Hanf M, Gras-Le Guen C. Reference ranges for serum S100B neuroprotein specific to infants under four months of age. Clin Biochem. 2017 Dec;50(18):1056-1060. doi: 10.1016/j.clinbiochem.2017.08.014.
Abbasoglu A, Sarialioglu F, Yazici N, Bayraktar N, Haberal A, Erbay A. Serum neuron-specific enolase levels in preterm and term newborns and in infants 1-3 months of age. Pediatr Neonatol. 2015 Apr;56(2):114-9. doi: 10.1016/j.pedneo.2014.07.005.
Laptook AR, Shankaran S, Tyson JE, et al. Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: a randomized clinical trial. JAMA. 2017 Oct 24;318(16):1550-1560. doi: 10.1001/jama.2017.14972.
Smit E, Liu X, Jary S, Cowan F, Thoresen M. Cooling neonates who do not fulfil the standard cooling criteria - short- and long-term outcomes. Acta Paediatr. 2015;104(2):138-45. doi: 10.1111/apa.12784.
Zaigham M, Lundberg F, Olofsson P. Protein S100B in umbilical cord blood as a potential biomarker of hypoxic-ischemic encephalopathy in asphyxiated newborns. Early Hum Dev. 2017 Sep;112:48-53. doi: 10.1016/j.earlhumdev.2017.07.015.
Bersani I, Auriti C, Ronchetti MP, Prencipe G, Gazzolo D, Dotta A. Use of early biomarkers in neonatal brain damage and sepsis: state of the art and future perspectives. Biomed Res Int. 2015;2015:253520. doi: 10.1155/2015/253520.
Negro S, Benders M, Tataranno ML, et al. Early prediction of hypoxic-ischemic brain injury by a new panel of biomarkers in a population of term newborns. Oxid Med Cell Longev. 2018;2018:7608108. doi: 10.1155/2018/7608108.
Copenhaver N, Huene M. Clinical utility of serum biomarkers for the management of neonatal hypoxic ischemic encephalopathy (control levels). ClinicalTrials.gov Identifier: NCT02349672. Available from: https://clinicaltrials.gov/ct2/show/NCT02349672. Accessed: June 21, 2018.
Copyright (c) 2019 CHILD`S HEALTH
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2019